Quadrant Capital Group LLC Has $53,000 Stake in Ionis Pharmaceuticals Inc (IONS)

Quadrant Capital Group LLC grew its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 2,839.1% in the first quarter, HoldingsChannel.com reports. The firm owned 676 shares of the company’s stock after buying an additional 653 shares during the quarter. Quadrant Capital Group LLC’s holdings in Ionis Pharmaceuticals were worth $53,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IONS. Mackay Shields LLC purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth $1,818,000. Capital Investment Advisory Services LLC purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth $91,000. BB Biotech AG lifted its stake in Ionis Pharmaceuticals by 0.9% in the fourth quarter. BB Biotech AG now owns 8,741,334 shares of the company’s stock worth $472,557,000 after acquiring an additional 75,000 shares during the period. Hanseatic Management Services Inc. purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth $440,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Ionis Pharmaceuticals by 82.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,709 shares of the company’s stock worth $957,000 after acquiring an additional 8,014 shares during the period. 84.28% of the stock is owned by hedge funds and other institutional investors.

IONS opened at $69.28 on Friday. The company has a quick ratio of 7.85, a current ratio of 7.88 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $9.68 billion, a price-to-earnings ratio of 23.41 and a beta of 2.31. Ionis Pharmaceuticals Inc has a 12-month low of $40.91 and a 12-month high of $86.58.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.19. The business had revenue of $297.00 million during the quarter, compared to the consensus estimate of $285.43 million. Ionis Pharmaceuticals had a return on equity of 49.13% and a net margin of 47.74%. The firm’s quarterly revenue was up 106.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.01) earnings per share. On average, equities analysts predict that Ionis Pharmaceuticals Inc will post -0.09 earnings per share for the current year.

A number of analysts recently commented on the company. Cantor Fitzgerald assumed coverage on Ionis Pharmaceuticals in a research note on Tuesday, April 9th. They issued a “neutral” rating and a $68.00 price target for the company. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. JPMorgan Chase & Co. raised their price target on Ionis Pharmaceuticals from $47.00 to $55.00 and gave the stock a “neutral” rating in a research note on Monday, March 18th. Piper Jaffray Companies set a $75.00 price target on Ionis Pharmaceuticals and gave the stock a “neutral” rating in a research note on Friday, March 22nd. Finally, ValuEngine raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 15th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. Ionis Pharmaceuticals has a consensus rating of “Hold” and an average price target of $66.44.

In other Ionis Pharmaceuticals news, SVP Richard S. Geary sold 999 shares of the stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $60.00, for a total value of $59,940.00. Following the completion of the transaction, the senior vice president now owns 21,442 shares in the company, valued at $1,286,520. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Frederick T. Muto sold 8,000 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $72.75, for a total value of $582,000.00. Following the completion of the transaction, the director now owns 17,794 shares of the company’s stock, valued at approximately $1,294,513.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 400,592 shares of company stock valued at $29,395,319. 2.44% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/12/quadrant-capital-group-llc-has-53000-stake-in-ionis-pharmaceuticals-inc-ions.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Read More: Intrinsic Value

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.